Prognostic significance of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma

Cancer

Volumn 83, Issue 2, 1998, Pages 276-282

  Tran, Tien Anh ^a   Kallakury, Bhaskar V S ^a   Ambros, Robert A ^a   Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Immunohistochemical staining; Nonsmall cell lung carcinoma; Prognosis; Tumor necrosis factors; Tumor necrosis receptors

Indexed keywords

LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032528225     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980715)83:2<276::AID-CNCR11>3.0.CO;2-Q     Document Type: Article

References (45)

1. Bazzori F, Beutler B. The tumor necrosis factor ligand and receptor families [review]. N Engl J Med 1996;334:1717-25.
2. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987;262:6951-4.
3. Jones EY, Stuart DI, Walker NP. Structure of tumour necrosis factor. Nature 1989;338:225-8.
4. Eck MJ, Sprang SR. The structure of tumor necrosis factor-alpha at 2.6-A resolution. Implications for receptor binding. J Biol Chem 1989;264:17595-605.
5. Eck MJ, Ultsch M, Rinderknecht E, de Vos AM, Sprang SR. The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. J Biol Chem 1992;267:2119-22.
6. Nedwin GE, Naylor SL, Sakaguchi AY, Smith D, Jarret-Nedwin J, Pennica D, et al. Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Res 1985;13:6361-73.
7. Gray PW, Aggarwal BB, Benton CV, Bringman TS, Henzel WJ, Jarrett JA, et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature 1984;312:721-4.
8. Schuchmann M, Hess S, Bufler P, Brakebusch C, Wallach D, Porter A, et al. Functional discrepancies between tumor necrosis factor and lymphotoxin alpha explained by trimer stability and distinct receptor interactions. Eur J Immunol 1995;25:2183-9.
9. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990;87:3127-31.
10. Hohmann HP, Remy R, Brockhaus M, van Loon AP. Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem 1989;264:14927-34.
11. Aggarwal BB. Structure of tumor necrosis factor and its receptor. Biotherapy 1991;3:113-20.
12. Hieber U, Heim ME. Tumor necrosis factor for the treatment of malignancies. Oncology 1994;51:142-53.
13. Miller YE, Pulmonary neoplasms. In: Bennett CJ, Plum F. Cecil textbook of medicine. 20th edition. Philadelphia: W.B. Saunders Co, 1996:436.
14. Yang SC, Grimm EA, Parkinson DR, Carinhas J, Fry KD, Mendiguren-Rodriguez A, et al. Clinical and immunomodulatory effects of combination immunotherapy with low dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial. Cancer Res 1991;51:3669-76.
15. Schiller JH, Morgan-Ihrig C, Levitt ML. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol 1995;18:47-51.
16. Cox DR. Regression models in life tables. J R Stat Soc Br 1972;32:187-98.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1957;53:457-81.
18. Schiller JH, Bittner G. Anti-proliferative effects of tumor necrosis factor, gamma interferon, and 5-fluorouracil on human colorectal carcinoma cell lines. Int J Cancer 1990;46:61-6.
19. Heim ME, Siegmund R, Illiger HJ, Klee M, Rieche K, Berdel WE, et al. Tumor necrosis factor in advanced colorectal cancer: a phase II study. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie 1990;13:444-7.
20. Kemeny N, Childs B, Larchian W, Rosado K, Kelsen D. A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 1990;66:659-63.
21. Skillings J, Wierzbicki R, Eisenhauer E, Venner P, Letendre F, Stewart D, et al. A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Immunother 1992;11:67-70.
22. Sherwood ER, Pitt Ford TR, Lee C, Kozlowski JM. Therapeutic efficacy of recombinant tumor necrosis factor alpha in an experimental model of human prostatic carcinoma. J Biol Response Mod 1990;9:44-52.
23. Lienard D, Lejeune FJ, Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992;16:234-40.
24. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993;91:2194-206.
25. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 1994;56:777-82.
26. Munker M, Munker R, Saxton RS, Koeffler HP. Effect of recombinant monokines, lymphokines, and other agents on clonal proliferation of human lung cancer cell lines. Cancer Res 1987;47:4081-5.
27. Hong WS, Jett JR, Sasaki Y, Takahashi H, Nakano H, Nakagawa K, et al. Colony inhibitory effect of recombinant human tumor necrosis factor (rH-TNF) and / or recombinant human interferon (rH-IFN)-alpha, -beta, and -gamma on human lung cancer cell lines. Jpn J Clin Oncol 1987;17:49-55.
28. Yang SC, Owen-Schaub LB, Grimm EA, Roth JA. Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets. Cancer Immunol Immunother 1989;29:193-8.
29. Ohkura M, Fuchimoto S, Orita K. Antitumor effect of recombinant human interleukin-1 beta alone and in combination with natural human tumor necrosis factor-alpha. Jpn J Cancer Res 1990;81:1026-31.
30. Naylor MS, Stamp GW, Balkwill FR. Investigation of cytokine gene expression in human colorectal cancer. Cancer Res 1990;50:4436-40.
31. Ito A, Sato T, Iga T, Mori Y. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS Lett 1990;269:93-5.
32. Higuchi M, Aggarwal BB. Modulation of two forms of tumor necrosis factor receptors and their cellular response by soluble receptors and their monoclonal antibodies. J Biol Chem 1992;267:20892-9.
33. Winzen R, Wallach D, Kemper O, Resch K, Holtmann H. Selective up-regulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1. J Immunol 1993;150:4346-53.
34. Poteu F, Hieblot C. Tumor necrosis factor induces a selective shedding of its p75 receptors from human neutrophils. J Biol Chem 1994;269:2834.
35. Schleiffenbaum B, Olgiati L, Fehr J. TNF-specific deactivation of granulocytes in vivo: a possible mechanism of self-protection. Eur J Haematol 1992;49:239-45.
36. Van der Poll T, Coyle SM, Kumar A, Barbosa K, Agosti JM, Lowry SF. Down-regulation of surface receptors for TNF and IL-1 on circulating monocytes and granulocytes during human endotoxemia: effect of neutralization of endotoxin-reduced TNF activity by infusion of a recombinant dimeric TNF receptor. J Immunol 1997;158:1490-7.
37. Higuchi M, Aggarwal BB. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol 1994;152:3550-8.
38. Pang XP, Ross NS, Hershman JM. Alterations in TNF-alpha signal transduction in resistant human papillary thyroid carcinoma cells. Thyroid 1996;6:313-7.
39. Petersen CM, Nykjaer A, Christiansen BS, Heickendorff L, Mogensen SV, Moller B. Bioactive human recombinant tumor necrosis factor-alpha: an unstable dimer? Eur J Immunol 1989;19:1887-94.
40. Moller B, Mogensen SC, Wendelboe P, Bendtzen K, Petersen CM. Bioactive and inactive forms of tumor necrosis factor-alpha in spinal fluid from patients with meningitis. J Infect Dis 1995;163:886-9.
41. Tartaglia LA, Pennica D, Goeddel D. Ligand bypassing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993;268:18542-8.
42. Espevik T, Brockhaus M, Loetscher H, Nonstad U, Shalaby MR. Characterization of binding and biologic effects of monoclonal antibodies against a human tumor necrosis factor receptor. J Exp Med 1990;171:415-26.
43. Shalaby MR, Sundan A, Loetscher H, Brockhaus M, Lesslauer W, Espevik T. Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J Exp Med 1990;172:1517-20.
44. Grell M, Scheurich P, Meager A, Pfizenmaier K. TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis. Lymphokine Cytokine Res 1993;12:143-8.
45. Vandenabeele P, Declercq W, Wanhaesebroeck B, Grooten J, Fiers W. Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol 1995;154:2904-13.